✦ LIBER ✦

Evaluation of the immune response to human papillomavirus types 16, 18, 31, 45 and 58 in a group of Colombian women vaccinated with the quadrivalent vaccine

✍ Scribed by Cómbita, Alba; Duarte, Diego; Rodríguez, Josefa; Molano, Mónica; Martínez, Lina; Romero, Pilar; Trujillo, Lina; González, Mauricio; Luna, Joaquín; Ortiz, Natascha; Hernández, Gustavo; Coursaget, Pierre; Touzé, Antoine

Book ID: 122644312
Publisher: Instituto Nacional de Cancerologia
Year: 2013
Tongue: English
Weight: 385 KB
Volume: 17
Category: Article
ISSN: 0123-9015
DOI: 10.1016/S0123-9015(13)70012-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Corrigendum to “Benefits of vaccinating

Corrigendum to “Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine” [Vaccine 28 (2010) 8065–8072]

✍ J. Monsonego; J. Cortes; C. Greppe; M. Hampl; E. Joura; A. Singer 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Response to Letter to the Editor by Tsu

Response to Letter to the Editor by Tsu et al. “Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine”

✍ Joseph Monsonego 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 122 KB

The impact of a quadrivalent human papil

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24

✍ S Majewski; FX Bosch; J. Dillner; O-E Iversen; SK Kjaer; N Muñoz; S-E Olsson; J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

Safety, immunogenicity, and efficacy of

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

✍ Nubia Muñoz; Ricardo Manalastas Jr; Punee Pitisuttithum; Damrong Tresukosol; Jos 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 171 KB

Safety, Immunogenicity, and Efficacy of

Safety, Immunogenicity, and Efficacy of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine in Women Aged 24–45 years: A Randomized, Double-blind Trial

✍ Corson, Stephen L. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 45 KB

The Health and Economic Impact of a Quad

The Health and Economic Impact of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) in Columbia: A Transmission Dynamic Model-Based Evaluation

✍ Kothari, S.; Nwankwo, C.; Pillsbury, M.; Shcheprov, A.; Posso, H. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB